Advances in medical therapy have improved outcomes for many ambulatory patients with heart failure and low ejection fraction (EF, a measure of how much blood the left ventricle of the heart pumps with each contraction), according to background information in the article. But every year an estimated 250000 to 300000 patients hospitalized for heart failure with low EF, and the 1-year survival rate for the hospital stay can be as low as 50 percent, even with recommended medical therapies. Recent studies have shown that the pulmonary artery catheter (PAC), a device to monitor hemodynamic status and guide therapy, may increase the risk of death for hospital patients. The randomized controlled trial included 433 patients at 26 sites and was conducted from January 18, 2000, to November 17, 2003. Patients were randomly assigned to receive clinical assessment and a PAC or clinical assessment alone. The main objective in both groups was resolution of clinical congestion, with other targets based on levels of pulmonary artery and right atrial pressure. The researchers found that therapy in both groups resulted in a substantial reduction in symptoms, jugular vein pressure, and edema (swelling from an accumulation of fluid). The use of the CAP does not significantly affect the primary end point of days alive and outside the hospital during the first 6 months (133 days vs. 135 days), death (43 patients [10 percent] vs. 38 patients [9 percent] ), Or the number of days of hospitalization (8.7 vs. 8.3). At the hospital adverse events were more common among patients in the group of PAC (47 [21.9 percent] vs. 25 [11.5 percent]). There were no deaths related to the use of PAC, and no difference in hospital-more than 30 days mortality (10 [4.7 percent] vs. 11 [5.0 percent]). Exercise and improved quality of life endpoints in both groups with a trend toward greater improvement with the PAC, which reached significance for the time trade-off at all time points after randomization.
"The ESCAPE trial defined the most compromised patients are studied in a National Heart Lung Blood Institute heart failure trial with medical therapy, with 19 percent (83 patients) mortality after 6 months. Nr. Diagnostic test in itself will improve results. New strategies must be developed to test both the interventions and the targets which they must be aligned. Although most trials in a high-event population have focused on reducing mortality, patients with advanced heart failure express willingness to trade survival time for better health in the time remaining. How patients value their daily lives should help in the design and evaluation of new therapies, " the authors conclude.
"Based on ESCAPE, there is no indication for the routine use of PAHs to adjust during the lengthy hospitalization for decompensation of heart failure. It seems likely that a number of patients and some therapies that better results with PAC monitoring and others counter harmful effects, "write the authors. "For patients whose signs and symptoms of congestion do not resolve with initial therapy, treatment of PAC monitoring at experienced sites appears reasonable if the information may guide further choices of therapy.
The PAC is acclimated to analyze assorted diseases and physiological states, adviser the advance of alarmingly ill patients, and adviser the alternative and acclimation of medical therapy, according to accomplishments advice in the article. The PAC is generally advised a cornerstone of analytical affliction and a authentication of the accelerated affliction assemblage (ICU). Approximately 1 actor PACs are acclimated annually in the United States. However, admitting boundless use of these devices, there is adverse abstracts about their effectiveness, and whether they access accident of affliction and death. Since the mid-1980s, randomized analytic trials (RCTs) accept been conducted to appraise the ability of the PAC. However, none of these trials accept been actuating individually, because they are bound by baby sample sizes in amalgamate populations. Admitting the overwhelmingly abrogating outcomes of the literature, clinicians abide to use the PAC in ICUs based on claimed acquaintance and the acceptance that accurate ecology will advance accommodation authoritative and analytic outcomes.
"Over the past 60 years, the CAP has evolved from a simple diagnostic tool to a device which is used for monitoring and determining objectives directed therapy. Our meta-analysis shows that despite the general acceptance of the CAP, the use of this device through a variety of clinical circumstances in critically ill patients does not improve survival or decrease the number of days hospitalized. These results suggest that the CAP should not be used for routine treatment of patients in intensive care, patients with decompensated heart failure, or patients until undergoing surgery or less effective can be found that improve outcomes when coupled with a diagnostic tool ", the authors conclude.
"Our meta-analysis of 13 RCTs evaluating the safety and effectiveness of the PAC shows that the use of the catheter or improves the outcome of critically ill patients nor increases mortality or days of hospitalization. This allows a broader confirmation of recent results of evasion trial, Who has shown that the routine use of the PAC in patients with advanced heart failure did not reduce or increase death or days in hospital," the authors write.
"There should be a positive result attributable to PAC in this trial, a specific niche for this technology can remain in the critical care area. If the results of this soon-to-be-completed trial show no benefit of PAC monitoring, it is likely that the available data indicate that is it time to remove the catheter from widespread use, or at least relegate this former common monitoring tool to salvage therapy of an extremely small and select number of patients. The need to question the routine use of this monitoring modality was very real and the results of the last 5 years of study most valuable. Once again the community of medical care were built with the approach of "Do not just do something, stand there! And after thinking about it…" Dr. Hallington concludes.
"What is the evidence for the broader issue use of PAC in the ICU and peri configuration? The data collected to date certainly do not support routine use of the catheter in any group of patients, and information currently available could be seen as justifying 'pulling the pulmonary artery catheter "in current use, a suggestion made almost 10 years ago. One important additional trial is nearing completion and evaluates the use of PAC in patients with adult respiratory distress syndrome."
